-
公开(公告)号：US20230176074A1
公开(公告)日：2023-06-08
申请号：US17917907
申请日：2021-04-09
Applicant: B.R.A.H.M.S GmbH
Inventor： Michael Hausmann , Ingo Curdt , Stefan Gehrig , Christiane Dinter
IPC: G01N33/68
CPC classification number: G01N33/6893 , G01N2333/4703 , G01N2333/4745 , G01N2800/127
Abstract: The present invention relates to a method for diagnosing a respiratory tract infection in a subject, comprising determining in a sample from said subject the level of High-Mobility-Group-Protein B1 (HMGB1), and/or determining in a sample from said subject the level of a histone protein, and/or determining in a sample from said subject the level of Insulin-like growth factor binding protein, acid labile subunit (IGFALS), wherein the subject is diagnosed with a bacterial respiratory tract infection when the level of IGFALS is below a predetermined threshold level and/or the level of the histone protein is above a predetermined threshold value, and/or wherein the subject is diagnosed with a respiratory tract infection when the level of HMGB1 is above a predetermined threshold level.
-
公开(公告)号：US20220221474A1
公开(公告)日：2022-07-14
申请号：US17710329
申请日：2022-03-31
Applicant: B.R.A.H.M.S GmbH
Inventor： Aline PEHLA , Stefan KIRSCH , Darius WILSON
Abstract: The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.
-
公开(公告)号：US11327082B2
公开(公告)日：2022-05-10
申请号：US16646798
申请日：2018-09-13
Applicant: B.R.A.H.M.S GmbH
Inventor： Aline Pehla , Stefan Kirsch , Darius Wilson
Abstract: The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.
-
公开(公告)号：US20210109117A1
公开(公告)日：2021-04-15
申请号：US16956036
申请日：2018-12-20
Applicant: B.R.A.H.M.S GmbH
Inventor： Aline PEHLA , Darius WILSON
IPC: G01N33/74
Abstract: The present invention is in the field of clinical diagnostics. Particularly, the present invention relates to the assessment of severity of a subject being suspected of an infection or having an infection, who may have physiological signs or increased risk factors for infection, in particular from an infectious disease by determination of the levels of Procalcitonin (hereinafter: PCT) (SEQ ID No: 1 and/or proadrenomedullin (hereinafter: proADM)) (SEQ ID No: 3) or a partial peptide or fragment thereof, in particular midregional proadrenomedullin (MR-proADM) (SEQ ID No: 2), in a sample of a patient and the invention is related to a workflow hereto. Moreover, the invention refers to the assessment related to an infection like ruling out/in a patient and stratification, risk assessment, in particular to avoid rehospitalisation and hospital and post-discharge mortality.
-
公开(公告)号：US20190178894A1
公开(公告)日：2019-06-13
申请号：US16323951
申请日：2017-08-08
Applicant: B.R.A.H.M.S GmbH
Inventor： Tim ZIERA , Andre SCHOENICHEN , Anne INCAMPS , Manne KROP , Ingo CURDT , Pierre-Emmanuel CHARLES
Abstract: The present invention relates to diagnosis, prognosis, risk assessment, and/or risk stratification of an adverse event, particularly mortality, of a subject. The invention relates to a method that comprises determining a level of at least one histone, particularly histone H2B, H4, H2A and/or H3, in a sample of said subject, and wherein said level of at least one histone is indicative of said adverse event of said subject; and/or determining a level of proadrenomedullin (proADM) in a sample of said subject, and wherein said level of proADM is indicative of said adverse event of said subject. The invention further relates to kits for carrying out the methods of the invention.
-
Patent Agency Ranking
公开(公告)号：US20180348235A1
公开(公告)日：2018-12-06
申请号：US15779000
申请日：2016-11-24
Applicant: B.R.A.H.M.S GmbH
Inventor： Bernard VIGUÉ , Homa RAFI-NIKOUKHAH
CPC classification number: G01N33/74
Abstract: The present invention relates to a method for determining the extracellular volume status of a subject. The method comprises determining in a sample obtained from a subject the level of the marker proadrenomedullin (proADM) or a fragment thereof, preferably MR-proADM. Further, based on the level of proADM or a fragment thereof, the fluid balance is determined and wherein said fluid balance determines the extracellular volume status. Further, based on the level of proADM or a fragment thereof, the salt balance is determined and wherein said salt balance determines the extracellular volume status and salt retention. Further, the invention relates to a method for in vitro diagnosis, risk stratification, therapy control and/or operative control of a disorder or medical condition in a subject, wherein said extracellular volume status and salt retention of said subject is determined by the herein provided method. Further, the invention relates to a kit and/or a diagnostic device for carrying out the herein provided method.
-
公开(公告)号：US20180252732A1
公开(公告)日：2018-09-06
申请号：US15967868
申请日：2018-05-01
Applicant: B.R.A.H.M.S. GmbH
Inventor： Joachim Struck
CPC classification number: G01N33/74 , C07K7/16 , C07K16/26 , C07K2317/34 , G01N33/6878 , G01N2410/04
Abstract: Method of obtaining and/or verifying a binder to prepro-Vasopressin (SEQ ID NO. 1) or fragments thereof of at least 6 amino acids in length, including Copeptin (SEQ ID NO. 2), comprising at least one of the steps of: a) generating the binder using a developer comprising an amino acid sequence of at least 6 amino acids in length contained in an amino acid sequence corresponding to the C-terminal part but lacking amino acid 164 of prepro-Vasopressin (SEQ ID NO. 1); b) determining whether the binder is capable of binding to an amino acid sequence of at least 4 amino acids in length contained in an amino acid sequence corresponding to the C-terminal part but lacking amino acid 164 of prepro-Vasopressin (SEQ ID NO. 1); c) selecting and optionally isolating the binder from a plurality of binders which is capable of binding to an amino acid sequence contained in an amino acid sequence corresponding to the C-terminal part but lacking amino acid 164 of prepro-Vasopressin (SEQ ID NO. 1); d) carrying out binding assays with the binder in order to determine the ex vivo stability of prepro-Vasopressin or fragments thereof of at least 6 amino acids in length, including Copeptin, in a biological sample; e) carrying out binding assays with the binder and another binder for comparison purposes in order to determine the concentration of prepro-Vasopressin or fragments thereof of at least 6 amino acids in length, including Copeptin, in a biological sample; wherein the C-terminal part consists of amino acids 138 to 164 of prepro-Vasopressin (SEQ ID NO. 1), in order to obtain a binder or a mixture of binders capable of binding to an epitope contained in an amino acid sequence corresponding to amino acids 138 to 163 but lacking amino acid 164 of prepro-Vasopressin (SEQ ID NO. 1).
-
公开(公告)号：US09753039B2
公开(公告)日：2017-09-05
申请号：US15211802
申请日：2016-07-15
Applicant: B.R.A.H.M.S. GmbH
Inventor： Joachim Struck , John GF Cleland
CPC classification number: G01N33/68 , G01N33/6893 , G01N2333/585 , G01N2800/325 , G01N2800/50 , G01N2800/54 , G01N2800/56
Abstract: The present invention is in the field of clinical diagnostics. Particularly the present invention relates to the prognosis of adverse events in patients with stable chronic heart failure or being suspected of having stable chronic heart failure by determination of the level of Procalcitonin (PCT).
-
公开(公告)号：US20160320411A1
公开(公告)日：2016-11-03
申请号：US15211802
申请日：2016-07-15
Applicant: B.R.A.H.M.S. GmbH
Inventor： Joachim STRUCK , John GF CLELAND
IPC: G01N33/68
CPC classification number: G01N33/68 , G01N33/6893 , G01N2333/585 , G01N2800/325 , G01N2800/50 , G01N2800/54 , G01N2800/56
Abstract: The present invention is in the field of clinical diagnostics. Particularly the present invention relates to the prognosis of adverse events in patients with stable chronic heart failure or being suspected of having stable chronic heart failure by determination of the level of Procalcitonin (PCT).
-
公开(公告)号：US20160146840A1
公开(公告)日：2016-05-26
申请号：US14903893
申请日：2014-07-10
Applicant: B.R.A.H.M.S GMBH
Inventor： Joachim STRUCK , Tim ZIERA
CPC classification number: G01N33/74 , C07K16/26 , C07K2317/34 , C12N5/12 , G01N2333/575
Abstract: The present invention relates to an immunoassay method for the detection of augurin or a precursor or fragment thereof comprising contacting a sample suspected of comprising augurin or a precursor or fragment thereof with a first and second antibody specific for augurin or a precursor or fragment thereof, wherein said first and second antibodies or antigen-binding fragments or derivatives thereof are specific for epitopes comprised in the sequence spanning amino acids 71 to 107 of pre-augurin according to SEQ ID NO:1.
Abstract translation: 本发明涉及用于检测吉非糖苷或其前体或片段的免疫测定方法，其包括将疑似含有宏观神经元或其前体或片段的样品与对于巨核糖蛋白或其前体或片段特异性的第一和第二抗体进行接触，其中 所述第一抗体或第二抗体或其抗原结合片段或其衍生物对于跨越根据SEQ ID NO：1的前兆元素的氨基酸71至107的序列中的表位是特异性的。
-
-
-
-
-
-
-
-
-
Search Results
75
records
(took 0.025 seconds)
